Most Read News

EBITDA grew up by 43% YoY to touch ₹187 crore in Q4 FY25

They are the generic form of Absorica, a well-known prescription treatment for severe and hard to treat forms of nodular acne that the patient has not responded well to other treatments with.

The company’s revenue from operations was at ₹2,694.4 crore, down 11.7% from ₹3,052 crore in Q4 FY24.

Commissioned by the Andhra Pradesh government as part of its renewable energy drive, the project was awarded to Bondada Engineering.

Company's EBITDA Margin increased to 13.20% compared to 11.98% in the same period of the previous year

Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin.

The company’s operating EBITDA stood at ₹6,378 crore. EBITDA margin in the quarter was 14.2%.

Operating margins expanded sharply to 15.2% in the March quarter compared to 12% a year ago

The partnership is seeking to design and manufacture cutting-edge logistics and cargo drones for defence and civilian operations in the country.

The deal is for production and delivery of Universal Rocket Launchers ranging up to 300 km.